News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Provista Life Sciences LLC and International Health Technology Announce Agreement to Market and Sell Provista's BT Test(R) for Breast Cancer



6/30/2008 7:47:33 AM

PHOENIX--(BUSINESS WIRE)--Provista Life Sciences LLC (PLS) today announced that it has reached a strategic partnering agreement with International Health Technology (IHT) to release the company’s BT Test® into the United Kingdom (UK) and Ireland. The BT Test, a new blood test to aid healthcare providers in early breast cancer detection, will be provided through IHT’s women’s clinic for breast health, BreastHealth UK. PLS and IHT will introduce the BT Test into the UK and Ireland beginning this summer with a following expanded release to other European Union (EU) countries thereafter. Terms and conditions for the licensing agreement have yet to be disclosed.

International studies related to the limitations associated with mammography are well documented and support the fact that reliance on mammograms alone leads to both high levels of false negative results and extremely high levels of false positive results. BreastHealth UK assists women in the proactive management of their own breast health needs. The company provides breast screening using state-of-the-art technology and recognized experts in breast disease to identifying breast cancer early. The BT Test complements the clinics’ current programs to assist in the early detection of this devastating disease.

“The BT Test is an analytical tool that is based on a patient’s blood chemistry and is directly associated with the underlying pathology of breast cancer,” said William Gartner, President and Chief Executive Officer (CEO) of Provista Life Sciences. “Partnering with IHT and their BreastHealth UK clinics allows us to expand the availability of the BT Test to women and physicians in the UK and other EU countries.”

The BT Test, or Biomarker Translation Test, finds multiple cancer-related proteins in the blood and combines the results with the patient’s medical profile to help physicians in their efforts to find breast cancer as early as possible. Clinical research conducted on the BT Test showed an accuracy rate above 80 percent for all women. When used in conjunction with mammography and other diagnostic imaging procedures, the BT Test offers women the most comprehensive and cost-effective means to screen for breast cancer available today.

“Our partnership with PLS allows us to offer the women in the UK and Ireland quick and easy access to this breakthrough test to aid in the early detection of breast cancer and supports our BreastHealth UK personalized services surrounding overall breast health care,” said Troels Jordansen, Director of IHT. “The BT Test is an extremely important advancement in women’s healthcare, and we are pleased to be partnering with Provista on the international launch of this test.”

About Provista Life Sciences

Provista Life Sciences is a biotechnology diagnostics development and commercialization company that provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostics technologies into the domestic and global marketplace. For more information, visit the company’s Web site at www.ProvistaLS.com or call 001+602.224.5500.

About International Health Technology

International Health Technology provides personalized breast screening programs in the UK through BreastHealth UK using state-of-the-art technology and recognized experts in breast disease detection, management and care. For more information, visit the company’s Web site at www.breasthealthuk.com or call 011+44.1223.352200.

Contact:

Provista Life Sciences LLC Caroline Hardy, 602-224-5500 hardyc@ProvistaLS.com www.ProvistaLS.com

Source: Provista Life Sciences LLC


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES